FDA approval of a generic intravenous sugammadex formulation; regulatory action does not report efficacy or comparative clinical trial data.
Reported
Formulation 1 strength500MG BASE/5ML (EQ 100MG BASE/ML)
Formulation 2 strength200MG BASE/2ML (EQ 100MG BASE/ML)
Approval date2026-07-28